Neion Bio and Barnwell Bio Formed Partnership

The two New York City biotechnology firms have joined forces to enhance biosecurity in avian drug manufacturing.

Updated on Oct. 14, 2026 in Biotech

Neion Bio and Barnwell Bio Formed Partnership

Live Poll

Do you trust that new biosecurity technologies in manufacturing will ultimately lower costs for patients?

Neion Bio has announced a strategic collaboration with Barnwell Bio to integrate advanced biosurveillance technology into its production operations. The partnership aims to provide proactive health monitoring for the chicken flocks used in Neion Bio’s recombinant protein manufacturing.

Why it matters

The integration of metagenomic monitoring is intended to bolster biosecurity and flock health, ensuring more reliable biologics production. This move signals a push toward utilizing data-driven diagnostics to mitigate risks in specialized manufacturing environments.

Neion Bio utilizes a proprietary Raptor platform to produce recombinant proteins in chicken eggs. Barnwell Bio’s technology performs metagenomic analysis on environmental samples to generate microbial fingerprints for identifying pathogen spikes.

The players

Neion Bio

This New York City-based biotechnology firm uses genetic engineering to produce recombinant proteins within chicken eggs.

Barnwell Bio

This biotechnology company provides metagenomic biosurveillance services designed to monitor animal health.

The details

Neion Bio will deploy Barnwell Bio’s metagenomic tools to perform longitudinal flock health monitoring across its facilities. By identifying microbial signatures, the firms intend to detect potential health issues before they impact the manufacturing process.

Neion Bio was founded in 2024.
Barnwell Bio announced $6 million in seed financing in January 2026.
Neion Bio emerged from stealth in March 2026.
Neion Bio raised $23 million in Series A funding in June 2026.
The partnership was officially announced on October 14, 2026.

The Tech Race

This collaboration marks a shift toward integrating specialized genomic monitoring into established biologics production workflows. It positions Neion Bio against traditional manufacturing methods by prioritizing automated, data-driven biosecurity as a core operational feature.

For stakeholders in the pharmaceutical supply chain, this integration could lead to more stable production timelines for protein-based medicines. The improved biosecurity measures aim to reduce manufacturing interruptions and enhance the consistency of critical biologics.

The takeaway

Proactive health monitoring in biologics manufacturing highlights the increasing importance of digital surveillance in agriculture. Businesses looking to improve reliability are turning to integrated metagenomic platforms to safeguard their supply chains.